GAITHERSBURG, Md., Aug. 1, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology
company dedicated to developing and commercializing next-generation
vaccines for serious infectious diseases, today announced it will
report its second quarter 2022 financial results and operational
highlights on Monday, August 8, 2022,
following the close of U.S. financial markets. Details of the event
and replay are as follows:
Conference call
details:
|
|
Date:
|
August 8,
2022
|
Time:
|
4:30 p.m. U.S. Eastern
Daylight Time (EDT)
|
Dial-in number:
|
(833) 974-2381
(Domestic) or (412) 317-5774 (International)
|
Webcast:
|
ir.novavax.com/events
|
- Participants
will be prompted to request to join the Novavax, Inc.
call.
- To ensure a
timely connection, it is recommended that participants join at
least 10 minutes prior to the scheduled webcast.
|
|
|
Replay
details:
|
|
Date:
|
Available starting at
7:30 p.m. EDT, August 8, 2022 until 11:59 p.m. U.S. EDT, August 15,
2022
|
Dial-in number:
|
(877) 344-7529
(Domestic) or (412) 317-0088 (International)
|
Passcode:
|
9237495
|
Webcast:
|
ir.novavax.com/events,
until November 8, 2022
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that
promotes improved health globally through the discovery,
development, and commercialization of innovative vaccines to
prevent serious infectious diseases. The company's proprietary
recombinant technology platform harnesses the power and speed of
genetic engineering to efficiently produce highly immunogenic
nanoparticles designed to address urgent global health needs.
NVX-CoV2373, the company's COVID-19 vaccine, has received
authorization from multiple regulatory authorities globally,
including the U.S., EC and the WHO. The vaccine is currently under
review by multiple regulatory agencies worldwide, including for
additional indications and populations such as adolescents and as a
booster. In addition to its COVID-19 vaccine, Novavax is also
currently evaluating a COVID-seasonal influenza combination vaccine
candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373
and NanoFlu*, its quadrivalent influenza investigational vaccine
candidate, and is also evaluating an Omicron strain-based vaccine
(NVX-CoV2515) as well as a bivalent Omicron-based / original
strain-based vaccine. These vaccine candidates incorporate Novavax'
proprietary saponin-based Matrix-M adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us
on LinkedIn.
*NanoFlu identifies a recombinant hemagglutinin (HA) protein
nanoparticle influenza vaccine candidate produced by Novavax. This
investigational candidate was evaluated during a controlled phase 3
trial conducted during the 2019-2020 influenza season.
Contacts:
Investors
Alex Delacroix | 240-268-2022
ir@novavax.com
Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-2022-financial-results-and-operational-highlights-on-august-8-2022-301596821.html
SOURCE Novavax, Inc.